Digital health · Crowdsourced diagnosis
CrowdMed
A marketplace where patients paid a monthly fee to post an undiagnosed case, and a crowd of self selected “medical detectives” ranked the possible answers. Top tier venture money, one independent peer reviewed evaluation, and years of published objection from physicians.
One hundred strangers
In 2003 Carly Heyman was eighteen. She fell into a deep depression, slept fourteen hours a day, gained fifty pounds and woke in cold sweats. Her parents took her to sixteen specialists and ran up more than $100,000 in bills. None found the cause.
The answer came from a team at the NIH Undiagnosed Diseases Program: fragile X associated primary ovarian insufficiency, which affects about one woman in fifteen thousand. A hormone patch cleared her symptoms.
Her older brother Jared had built a career on survey methods and prediction markets. He ran an experiment. “With an early prototype, we tried to retroactively crowdsource the answer to my sister’s case using 100 randomly selected people and showing them the exact same information that her doctors had before she was diagnosed,” he told Smithsonian in 2015. The crowd named it in days. That result became a company.
The gap it aimed at
Formal help for hard cases was narrow. The NIH Undiagnosed Diseases Network screened applicants and required a referral. Best Doctors served only employee beneficiaries. The Cleveland Clinic ran a records based second opinion with no patient contact. The National Organization for Rare Disorders told NBC News that rare disease patients wait an average of seven years for an accurate diagnosis. CrowdMed offered no referral, no eligibility screen, and a conversation.
Three founders and a batch
Jared Heyman had founded the survey company Infosurv in 1998 and grown it past $20 million in aggregate revenue. Axel Setyanto, previously at Loku, was lead developer; Jessica Greenwalt, founder of the design firm Pixelkeet, was lead designer. CrowdMed came out of Y Combinator’s Winter 2013 class and launched its public beta at TEDMED that April with $1.1 million from NEA, Andreessen Horowitz, Greylock Partners, SV Angel and Y Combinator. By May 2014 the round stood at $2.4 million, adding Khosla Ventures and the actor Patrick Dempsey.
What a case cost
A patient filled in a questionnaire, uploaded records, and the case went live. Solvers suggested diagnoses and bet points on them. An algorithm ranked the suggestions, a licensed physician moderated, and the patient got a report to take to a doctor.
The price moved. Popular Science reported a $50 posting fee and a $99 monthly package in 2015; USA Today put it at $150 to $350 that November; by late 2016 The DO reported $149 to $749 per month, still the range Peninsula Press found in 2020. Patients also set aside rewards of $200 to $1,000 for the most useful solvers, and at least half of what they paid went to the detectives.
Who those detectives were is what drew fire. Anyone could sign up. In the 2016 evaluation, 58.3% of active solvers worked or studied in the medical industry, including 36 physicians and 56 medical students out of 357 people. Danyell Jones, then chief executive, called the mix deliberate, arguing that US physicians share a training background and therefore share blind spots.
Two papers and a rebuttal
In January 2016 the Journal of Medical Internet Research published an independent evaluation by Ashley N. D. Meyer, Christopher A. Longhurst and Hardeep Singh. CrowdMed supplied the raw data and, the paper states, did not fund, commission or shape it. Across 397 completed cases, 50.9% of patients said they would recommend the service and 59.6% said it gave insights bringing them closer to a correct diagnosis. No eventual diagnosis was verified. The authors also flagged “the potential legal ramifications of giving individuals without medical degrees (who make up a substantial portion of the case solvers) the ability to render diagnostic opinions”.
Five months later the same journal published a second paper, on health care use. Visits fell from 1.07 to 0.65 per month and charges from $719.70 to $516.79. Its funnel was stark: 546 eligible users, 45 completed surveys, 13 in the final sample. The disclosure reads that “Evidation Health, Inc. was paid by CrowdMed, Inc. to conduct this study.”
The lawyers moved first. In April 2015 Stanford Law School’s Law and Biosciences Blog set out California prohibitions on unlicensed diagnosis and on the corporate practice of medicine and asked, “But one obvious question is: How is this not the unauthorized practice of medicine?” No enforcement action has been found in the public record.
The sharpest clinical criticism came from Jeff Russ, then a child neurology resident at UCSF, on KevinMD in March 2017 and in the San Francisco Chronicle that May. His argument turned on sequence: a crowd ranks by popularity, a physician ranks by danger. He cited a case aired on the podcast Reply All in which imaging for a possible arterial dissection sat on the crowd’s list below chiropractic manipulation, which the patient pursued.
The last numbers on file
The 2016 crowdfunding raise put the books on the record: revenue of $282,981 in 2015 against a net loss of $802,014, six employees. Then the filings thin. The last, covering 2019, lists one employee, revenue of $127,787, cash of $79,073 and long term debt of $4,671,564. Jones signed as chief executive, Lee Jared Heyman as chairman. Nothing has been filed since June 2020.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Independent evaluation | Meyer, Longhurst and Singh, J Med Internet Res 2016;18(1):e12. 397 cases, May 2013 to April 2015. 50.9% likely to recommend; 59.6% reported insights leading closer to a correct diagnosis. Downstream outcomes were not collected. | Public record |
| Company success rate | Heyman told Smithsonian in 2015 the service had a 70 percent success rate, and NBC News in 2017 that “75 percent of the time, if a patient has a medically confirmed diagnosis, it came from us”. No study verified either figure. | Differs from the study |
| Company funded study | Juusola, Quisel, Foschini and Ladapo, PMID 27251384. Visits 1.07 to 0.65 per month (P=.01); charges $719.70 to $516.79 (P=.03). Funnel: 546 eligible, 45 surveys, 13 enrolled. Evidation Health was paid by CrowdMed to run it. | Public record |
| Published objection | Jeff Russ, MD, PhD, KevinMD and San Francisco Chronicle, 2017: ranking by popularity displaces ruling out emergencies. Stanford Law School’s blog, 2015, questioned the model under California licensing law. | Independent |
| Regulatory and legal record | No FDA clearance, registered trial or federal award found. No medical board or FTC action found to Sep 22, 2026. A December 2019 search of San Francisco civil dockets found no suits against CrowdMed. | Not found |
| Company financials | SEC Form C and C-AR, CIK 0001687611: revenue $124,862 (FY2014), $282,981 (FY2015), $127,787 (FY2019). Net loss $802,014 falling to $286,139.65. Headcount 6, then 4, then 2, then 1. | Public record |
| Group diagnosis, generally | Sherbino and colleagues, BMJ Qual Saf 2024;33(12), found group diagnosis more accurate than individual among residents, but six people were no better than three. | Public record |
| Current status | Wikipedia records the site as appearing down from Oct 16, 2023. A TEDMED speaker biography says CrowdMed was acquired in 2024; no SEC filing or independent report confirms a sale. | Claim unconfirmed |
Read plainly: the strongest independent finding is that most surveyed patients said the experience helped, and the authors of that finding wrote in the same paper that nobody had checked whether it did. The company’s 70 percent and the researchers’ 59.6 percent do not measure the same thing, and only one was produced outside the company. The criticism was never that crowds cannot diagnose; a 2024 comparison in BMJ Quality and Safety found groups beat individuals. It was that a popularity ranking is a poor instrument for ruling out what kills quickly, and that patients who had run out of options were paying for advice they had no way to grade.
What to watch
- Whether anyone publishes downstream outcome data. Both 2016 papers named that gap; neither closed it.
- Whether the acquisition stated in a speaker biography is ever documented anywhere else.
- Whether the notes sold to 608 crowd investors in 2017 were converted, repaid or written off.
- Whether crowdmed.com resumes accepting cases, and under whose oversight.
In their words
“This is why CrowdMed has a 70 percent success rate solving challenging cases that the medical system could not, and 95 percent of our final diagnoses have come up only once or twice ever on the site, which illustrates how rare and obscure these diagnoses are.”
Jared Heyman, founder and CEO, to Smithsonian, 2015 · Company-stated
“Our patients understand that your suggestions do no constitute medical advice and only their doctor can provide a definitive diagnosis and treatment plan.”
Jared Heyman, to Smithsonian, 2015 · Company-stated
“Furthermore, downstream outcomes of patients were not systematically collected, so it is not known what their eventual diagnoses were or if the program identified them accurately.”
Meyer, Longhurst and Singh, Journal of Medical Internet Research, 2016 · Peer reviewed
“We actually don’t know the downstream outcomes of the suggestions coming out of the crowd, which is exactly why we need that evaluation component.”
Hardeep Singh, MD, MPH, Baylor College of Medicine, to NBC News, 2017 · Independent
“The critical lesson: Ruling out dangerous diagnoses supersedes reaching the right answer.”
Jeff Russ, MD, PhD, child neurology resident, KevinMD, 2017 · Independent
“The diagnostic crowdsourcing companies however exploit this desperation.”
Jeff Russ, MD, San Francisco Chronicle Open Forum, 2017 · Independent
“We are not practicing medicine,”
Danyell Jones, CEO, to Peninsula Press, 2020 · Company-stated
Related companies
Sources
- Public recordCrowdsourcing Diagnosis for Patients With Undiagnosed Illnesses: An Evaluation of CrowdMed
- Public recordThe Impact of an Online Crowdsourcing Diagnostic Tool on Health Care Utilization
- Public recordCrowdsourcing a diagnosis? Accuracy of the size and type of group diagnosis
- Public recordMapping of Crowdsourcing in Health: Systematic Review
- Public recordCommentary on the CrowdMed evaluation
- Public recordSEC EDGAR filings, CrowdMed, Inc., CIK 0001687611
- IndependentThe dangers of inexpert diagnosis from a noisy crowd
- IndependentThe dangers of crowdsourced medicine
- IndependentCrowdsourcing Medicine?
- IndependentIn the Wild West of online medicine, crowdsourcing is the next frontier
- IndependentHow internet detectives are helping diagnose rare disorders
- IndependentWould you trust Internet sleuths to diagnose rare disease?
- IndependentYou Can Now Crowdsource Your Medical Diagnoses, But Should You?
- IndependentCrowdMed’s ‘medical detectives’ tackle tricky cases online
- IndependentCrowdMed and crowdsourcing of medical advice online
- IndependentYC-Backed CrowdMed Launches To Crowdsource Medical Diagnoses
- IndependentPatrick Dempsey contributes to CrowdMed’s $2.4M seed round
- CompanyCan You Crack a Medical Mystery? Interview with Jared Heyman
- CompanyCrowdMed Wefunder profile and quick facts
- CompanyJared Heyman speaker biography
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
